SEC Filing Analysis: Avidity Biosciences, Inc. (RNA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Program Officer acquired 72,000 shares (valued at ~$5.17M) from the vesting of performance-based stock units, with a portion automatically withheld for tax purposes. This is a non-discretionary compensation event.
• Market Impact: Neutral. The transaction is a pre-planned compensation event, not an open-market trade reflecting new insider sentiment.

Company Information

Field	Value
Company	Avidity Biosciences, Inc.
Ticker Symbol	RNA
CIK	0001599901
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Gallagher Kathleen P.
CIK	0002048409
Title/Position	Chief Program Officer
Relationship	Officer

Transaction Details

This filing reports a stock grant and subsequent automatic disposals for tax withholding.

Transaction 1: Stock Grant

Field	Value
Form Type	4
Transaction Date	2025-12-17
Transaction Code	A (Grant)
Security Type	Common Stock
Shares Involved	72,000
Price Per Share	$0.00
Total Value	$0
Ownership Type	Direct

Transaction 2 & 3: Tax Withholding

Field	Value
Transaction Code	F (Tax Withholding)
Shares Involved	41,366 (33,336 + 8,030)
Price Per Share	$71.87
Total Value	$2,973,230.02
Ownership Type	Direct

Net Position Change

Field	Value
Net Shares Acquired	30,634
Shares Owned After	80,838

Financial Impact Assessment

Transaction Materiality

Metric	Value
Grant Market Value	~$5,174,640 (72,000 shares @ $71.87)
% of Market Cap	~0.048%
Shares Transacted	72,000 (Grant)
% of Shares Outstanding	Not Available
Post-Transaction Ownership	80,838 shares
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $10.67 billion, a grant valued at ~$5.17 million represents a very small fraction (less than 0.05%) of the company's total value. It is not a market-moving event.
• Transaction Significance: The significance is low from a market perspective. It is a routine part of an executive compensation plan, not a discretionary investment decision. The value is substantial for the individual but immaterial relative to the company's size.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transactions are the result of a pre-scheduled vesting of performance stock units and automatic tax withholding. They do not reflect a new decision by the insider to increase or decrease their exposure to the company based on current information.

Volume & Sentiment

• Expected Volume Impact: Minimal. The disposition for taxes is handled by the issuer and does not represent an open-market sale that would impact trading volume.
• Sentiment Indicator: Neutral. This filing provides no new information on the insider's sentiment towards the company's future prospects.

Additional Context

Transaction Notes

• Footnote F1: The 72,000 shares were acquired upon the vesting of performance-based restricted stock units (PSUs) granted in October 2024. The settlement was accelerated for tax planning purposes.
• Footnotes F2 & F3: A total of 41,366 shares were automatically withheld by Avidity Biosciences to cover the insider's tax liabilities associated with the vesting of PSUs and other restricted stock units. This is a common "sell-to-cover" transaction and not a discretionary sale.